method of obtaining u0433u0435u043fu0430u0442u043eu043fu0440u043eu0442u0435u043au0442u043eu0440u043du043eu0433u043e means on the basis of u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 kidney poplar balsamic (POPULUS BALSAMIFERA l.)

摘要

the invention belongs to the field of bioorganic chemistry, pharmaceutical chemistry and drug technology and the ways of obtaining drugs from plant to u044bu0440u044cu044f with u0433u0435u043fu0430u0442u043eu043fu0440u043eu0442u0435u043au0442u043eu0440u043du043eu0439 activity.the technical result of the declared invention is achieved, that is environmentally safe u0431u0430u0440u043eu0442u0435u0440u043cu0438u0447u0435u0441u043au0438u0439 way to obtain extract kidneys topo la balsamic (Populus balsamiferaL.with the content u0444u043bu0430u0432u043eu043du043eu0438u0434u0430 u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 0.9% over the air to dry the raw materials, the raw materials at the temperature of 150 to 160u00b0u0441 least read several others, the pressure of 1 atm for 60 min. the separation and treatment of deep u043au043eu043bu043eu043du043eu0447u043du043eu0439 chromatography method with u044du043bu044eu0438u0440u043eu0432u0430u043du0438u0438 u043fu0435u0442u0440u043eu043bu0435u0439u043du044bu043c ether and a mixture of petroleum ether and ethyl acetate 49: 1u043fu0435u0440u0435u043au0440u0438u0441u0442u0430u043bu043bu0438u0437u0430u0446u0438u0435u0439 dedicated technical u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 and fusion based on u043eu043au0441u0438u043cu0430 u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 (substance for drug form).substance u043eu043au0441u0438u043cu0430 u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 not toxic, not to cause acute toxic reactions when tested in mice and rats, and has high u0433u0435u043fu0430u0442u043eu043fu0440u043eu0442u0435u043au0442u043eu0440u043du0443u044e u0430u043au0442u0438u0432u043d spine in a dose of 100 mg / kg body weight, and in a dose of 50 mg / kg and manifestations of symptoms u0446u0438u0442u043eu043bu0438u0437u0430, u0445u043eu043bu0435u0441u0442u0430u0437u0430 and u043cu0435u0437u0435u043du0445u0438u043cu0430u043bu044cu043du043eu0433u043e inflammation. u043eu043au0441u0438u043c u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 refers to "u043au043eu0440u043eu0442u043au043eu0436u0438u0432u0443u0449u0438u043c" drugs.in the body of rats the drug is determined for 2 h, irrespective of the applied dose and mode of introduction, it is mainly in the u0432u0430u0441u043au0443u043bu044fu0440u0438u0437u0438u0440u043eu0432u0430 u043du043du044bu0435 organs (kidneys, liver, lungs) and absolute bioavailability of u043eu043au0441u0438u043cu0430 u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 is 11%. u0430u043du0442u0438u043eu043au0441u0438u0434u0430u043du0442u043du0430u044f activity u043eu043au0441u0438u043cu0430 u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 20 times compared with the u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du043eu043c.u043eu043au0441u0438u043c u043fu0438u043du043eu0441u0442u0440u043eu0431u0438u043du0430 has no toxic effect on the liver, reduces the intensity of the u043bu0438u043fu043eu043fu0435u0440u043eu043au0441u0438u0434u0430u0446u0438u0438, content u0442u0440u0438u0430u0446u0438u043bu0433u043bu0438u0446u0435u0440u0438u0434u043eu0432 at 26% and increases of u0444u043eu0441u0444u043eu043bu0438u043fu0438u0434u043eu0432 of 21%, inhibits lipid oxidation processes u043fu0435u0440u0435u043au0438u0441u043du043eu0433u043e u0433u0435u043fu0430u0442u043eu0446u0438u0442u0430u0445, lowering the content of u0434u0438u0435u043du043eu0432u044bu0445 u043au043eu043du044au044eu0433u0430u0442u043eu0432 at 35%.increasing the activity of enzymes u0430u043du0442u0438u043fu0435u0440u0435u043au0438u0441u043du043eu0439 protection - glutathione peroxidase and u0433u043bu0443u0442u0430u0442u0438u043eu043du0440u0435u0434u0443u043au0442u0430u0437u044b to 54%.